{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-057139","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.680653+00:00","generated_at":"2026-06-15T12:34:35.300371+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocular Therapeutix Q1 net loss widens to $30.3M; DEXTENZA rev up 6% to $13.2M","bullets":["Net loss of $30.3M ($0.39/share) vs $12.5M ($0.16/share) in Q1 2022; includes $6.6M non-cash derivative fair value charge.","DEXTENZA net product revenue $13.2M (+6% YoY); total net revenue $13.4M. FY2023 revenue guidance reiterated at $55-60M.","Cash & equivalents $79.0M at Mar 31, 2023 (down from $102.3M); cash runway to mid-2024 excluding planned OTX-TKI trials.","OTX-TKI wet AMD Phase 1 12-month data to be presented June 2023; potentially start pivotal trial in Q3 2023.","OTX-TIC glaucoma Phase 2 enrolling; top-line data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-057139","json":"https://secwatch.observer/filing/0001104659-23-057139.json","markdown":"https://secwatch.observer/filing/0001104659-23-057139.md","text":"https://secwatch.observer/filing/0001104659-23-057139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/0001104659-23-057139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/tm2314977d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:34:35.300371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ca5d524c75e70ed2ad4e15ddfc5fdb10689d2ea","claim":"OCULAR THERAPEUTIX, INC reported the first quarter ended March 31, 2023 results: revenue $13.2 million. Guidance reaffirmed.","evidence_excerpt":"Net product revenue of DEXTENZA for the first quarter of 2023 was $13.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923057139/0001104659-23-057139-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$13.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}